ArticleOncogene2020
Resistance to the CHK1 inhibitor prexasertib involves functionally distinct CHK1 activities in BRCA wild-type ovarian cancer.
Jayakumar Nair et al.PubMed ↗Full text ↗Publisher ↗
No numbers read from the abstract.
34 papers cite it
this papertrialcites it